Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma

Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence f...

Full description

Saved in:
Bibliographic Details
Published inJournal of Clinical Investigation Vol. 130; no. 11; pp. 5833 - 5846
Main Authors Chan, Jason Yongsheng, Lim, Jing Quan, Yeong, Joe, Ravi, Vinod, Guan, Peiyong, Boot, Arnoud, Tay, Timothy Kwang Yong, Selvarajan, Sathiyamoorthy, Md Nasir, Nur Diyana, Loh, Jie Hua, Ong, Choon Kiat, Huang, Dachuan, Tan, Jing, Li, Zhimei, Ng, Cedric Chuan-Young, Tan, Thuan Tong, Masuzawa, Mikio, Sung, Ken Wing-Kin, Farid, Mohamad, Quek, Richard Hong Hui, Tan, Ngian Chye, Teo, Melissa Ching Ching, Rozen, Steven George, Tan, Patrick, Futreal, Andrew, Teh, Bin Tean, Soo, Khee Chee
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.11.2020
Subjects
Angiosarcoma
Biomedical research
Cancer immunotherapy
Care and treatment
CD8 antigen
Cell Line, Tumor
Cytotoxicity
Diagnosis
DNA methylation
DNMT1 protein
Epigenetics
Female
Foxp3 protein
Gene expression
Genetic aspects
Genomes
Head and neck
Hemangiosarcoma
Hemangiosarcoma - classification
Hemangiosarcoma - genetics
Hemangiosarcoma - immunology
Humans
Immunofluorescence
Immunohistochemistry
Immunotherapy
Inflammation
Inflammation - classification
Inflammation - genetics
Inflammation - immunology
Leukocytes (neutrophilic)
Lymphedema
Lymphocytes T
Macrophages
Male
Medical prognosis
Methods
Molecular diagnostic techniques
Mutation
Myc protein
Neck
Neoplasm Proteins
Neoplasm Proteins - genetics
Neoplasm Proteins - immunology
Oncology
Patients
PD-L1 protein
Precision medicine
Radiation therapy
Tumor-infiltrating lymphocytes
Tumors
Whole genome sequencing
Singapore
Genetics
Oncology
Cancer immunotherapy
Bioinformatics
Cancer
Online AccessGet full text

Cover

Abstract Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non-UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15+), macrophages (CD68+), cytotoxic T cells (CD8+), Tregs (FOXP3+), and PD-L1+ cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.
AbstractList Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non-UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune- related signaling and immune cells. Neutrophils ([CD15.sup.+]), macrophages ([CD68.sup.+]), cytotoxic T cells ([CD8.sup.+]), Tregs ([FOXP3.sup.+]), and [PD-L1.sup.+] cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.
Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non-UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15·), macrophages (CD68·), cytotoxic T cells (CD8·), Tregs (FOXP3·), and PD-L1· cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.
Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non-UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15+), macrophages (CD68+), cytotoxic T cells (CD8+), Tregs (FOXP3+), and PD-L1+ cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.
Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non-UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15+), macrophages (CD68+), cytotoxic T cells (CD8+), Tregs (FOXP3+), and PD-L1+ cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non-UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15+), macrophages (CD68+), cytotoxic T cells (CD8+), Tregs (FOXP3+), and PD-L1+ cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.
Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing ( n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non–UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15 + ), macrophages (CD68 + ), cytotoxic T cells (CD8 + ), Tregs (FOXP3 + ), and PD-L1 + cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1 , BRD3/4 , MYC , HRAS , and PDGFRB , in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.
Audience Academic
Author Steven G. Rozen
Choon Kiat Ong
Jason Yongsheng Chan
Andrew Futreal
Melissa Ching Ching Teo
Joe Yeong
Jing Tan
Zhimei Li
Nur Diyana Md Nasir
Mohamad Farid
Peiyong Guan
Thuan Tong Tan
Richard Quek
Cedric Chuan Young Ng
Timothy Kwang Yong Tay
Arnoud Boot
Khee Chee Soo
Patrick Tan
Ngian Chye Tan
Sathiyamoorthy Selvarajan
Jing Quan Lim
Jie Hua Loh
Vinod Ravi
Ken Wing-Kin Sung
Mikio Masuzawa
Bin Tean Teh
Dachuan Huang
AuthorAffiliation 1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
3 SingHealth Duke-NUS Blood Cancer Centre, Singapore
16 Division of Surgical Oncology, National Cancer Centre Singapore, Singapore
13 Department of Regulation Biochemistry, School of Allied Health Sciences, Kitasato University, Minato City, Tokyo, Japan
11 Laboratory of Cancer Epigenome, Division of Medical Sciences National Cancer Centre Singapore, Singapore
12 Department of Infectious Diseases, Singapore General Hospital, Singapore
5 Department of Anatomical Pathology, Singapore General Hospital, Singapore
9 Centre for Computational Biology, and
2 Cancer Science Institute of Singapore, National University of Singapore, Singapore
10 Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
19 Division of Cellular and Molecular Research, National Cancer Centre Singapore
7 Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6 Institute of Molecular and
AuthorAffiliation_xml – name: 2 Cancer Science Institute of Singapore, National University of Singapore, Singapore
– name: 17 SingHealth Duke-NUS Head and Neck Centre, Singapore
– name: 16 Division of Surgical Oncology, National Cancer Centre Singapore, Singapore
– name: 1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
– name: 12 Department of Infectious Diseases, Singapore General Hospital, Singapore
– name: 14 Genome Institute of Singapore, ASTAR, Singapore
– name: 18 Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– name: 5 Department of Anatomical Pathology, Singapore General Hospital, Singapore
– name: 15 School of Computing, National University of Singapore, Singapore
– name: 10 Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
– name: 3 SingHealth Duke-NUS Blood Cancer Centre, Singapore
– name: 6 Institute of Molecular and Cell Biology, Singapore
– name: 7 Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– name: 9 Centre for Computational Biology, and
– name: 4 Lymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore
– name: 19 Division of Cellular and Molecular Research, National Cancer Centre Singapore
– name: 8 Integrated Biostatistics and Bioinformatics Programme
– name: 11 Laboratory of Cancer Epigenome, Division of Medical Sciences National Cancer Centre Singapore, Singapore
– name: 13 Department of Regulation Biochemistry, School of Allied Health Sciences, Kitasato University, Minato City, Tokyo, Japan
Author_xml – sequence: 1
  givenname: Jason Yongsheng
  orcidid: 0000-0002-4801-3703
  surname: Chan
  fullname: Chan, Jason Yongsheng
– sequence: 2
  givenname: Jing Quan
  orcidid: 0000-0003-3732-8707
  surname: Lim
  fullname: Lim, Jing Quan
– sequence: 3
  givenname: Joe
  surname: Yeong
  fullname: Yeong, Joe
– sequence: 4
  givenname: Vinod
  surname: Ravi
  fullname: Ravi, Vinod
– sequence: 5
  givenname: Peiyong
  orcidid: 0000-0001-9958-0137
  surname: Guan
  fullname: Guan, Peiyong
– sequence: 6
  givenname: Arnoud
  orcidid: 0000-0002-7717-7416
  surname: Boot
  fullname: Boot, Arnoud
– sequence: 7
  givenname: Timothy Kwang Yong
  orcidid: 0000-0001-8592-5018
  surname: Tay
  fullname: Tay, Timothy Kwang Yong
– sequence: 8
  givenname: Sathiyamoorthy
  surname: Selvarajan
  fullname: Selvarajan, Sathiyamoorthy
– sequence: 9
  givenname: Nur Diyana
  surname: Md Nasir
  fullname: Md Nasir, Nur Diyana
– sequence: 10
  givenname: Jie Hua
  surname: Loh
  fullname: Loh, Jie Hua
– sequence: 11
  givenname: Choon Kiat
  orcidid: 0000-0001-6402-4288
  surname: Ong
  fullname: Ong, Choon Kiat
– sequence: 12
  givenname: Dachuan
  orcidid: 0000-0002-7518-4081
  surname: Huang
  fullname: Huang, Dachuan
– sequence: 13
  givenname: Jing
  surname: Tan
  fullname: Tan, Jing
– sequence: 14
  givenname: Zhimei
  surname: Li
  fullname: Li, Zhimei
– sequence: 15
  givenname: Cedric Chuan-Young
  surname: Ng
  fullname: Ng, Cedric Chuan-Young
– sequence: 16
  givenname: Thuan Tong
  surname: Tan
  fullname: Tan, Thuan Tong
– sequence: 17
  givenname: Mikio
  surname: Masuzawa
  fullname: Masuzawa, Mikio
– sequence: 18
  givenname: Ken Wing-Kin
  surname: Sung
  fullname: Sung, Ken Wing-Kin
– sequence: 19
  givenname: Mohamad
  surname: Farid
  fullname: Farid, Mohamad
– sequence: 20
  givenname: Richard Hong Hui
  surname: Quek
  fullname: Quek, Richard Hong Hui
– sequence: 21
  givenname: Ngian Chye
  surname: Tan
  fullname: Tan, Ngian Chye
– sequence: 22
  givenname: Melissa Ching Ching
  surname: Teo
  fullname: Teo, Melissa Ching Ching
– sequence: 23
  givenname: Steven George
  surname: Rozen
  fullname: Rozen, Steven George
– sequence: 24
  givenname: Patrick
  orcidid: 0000-0002-0179-8048
  surname: Tan
  fullname: Tan, Patrick
– sequence: 25
  givenname: Andrew
  surname: Futreal
  fullname: Futreal, Andrew
– sequence: 26
  givenname: Bin Tean
  orcidid: 0000-0003-1514-1124
  surname: Teh
  fullname: Teh, Bin Tean
– sequence: 27
  givenname: Khee Chee
  surname: Soo
  fullname: Soo, Khee Chee
BackLink https://cir.nii.ac.jp/crid/1872835443048720256$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/33016928$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1rFDEUhoNU7LZ64R-QAUX0Ytp8J3MjlMWPlUpBrbchk8nMZplJ1kmmuP_eLNuvlb2QQHIgz3nPSc57Ao588BaAlwieISTw-co4RCoo4RMwQ4zJUmIij8AMQozKShB5DE5iXEGIKGX0GTgmBCJeYTkD19-mPrkwOFNor_tNdDEHTeGGYfJhPYbW9c53xWhvrO6LxsXkvElFnOq0WdtYhLZYToP2OatzIerRhEE_B09b3Uf74vY8BdefPv6cfykvrz4v5heXpREQp1LUlLTS8rbhLa1ITaWpGaJG5kaZbnhdaV7VWlBDGK5abNsaZb7BzFJsCSSn4MNOdz3Vg22M9WnUvVqPbtDjRgXt1P6Nd0vVhRslWCUhR1ng3a3AGH5PNiY1uGhs32tvwxQVplRywjhnGX39D7oK05j_bEsxKQTnuHqgOt1b5Xwbcl2zFVUXnCLIBMciU-UBqrPe5ibzbPOn233-7ACfV2Pz5A4mvN9LyEyyf1KnpxjV4sf3_2evfu2zbx-xy2yJtIyhn7KFfNwHXz2ezP1I7pyXgfMdYMYQ42hbZVzSW538NNcrBNXW2-rrfLHz9kOf9xl3oofYNzvWO5eFtzuSIpdllBJIcwgx4-QvCkP_qw
CitedBy_id crossref_primary_10_1158_1541_7786_MCR_20_0937
crossref_primary_10_3390_ijms23147839
crossref_primary_10_3389_fimmu_2024_1515935
crossref_primary_10_3390_ijms251910863
crossref_primary_10_1186_s13000_024_01534_w
crossref_primary_10_1111_jop_13354
crossref_primary_10_1093_jnen_nlae101
crossref_primary_10_3389_fcell_2022_805507
crossref_primary_10_1111_ddg_14694_g
crossref_primary_10_1007_s12026_021_09259_4
crossref_primary_10_1158_2767_9764_CRC_23_0441
crossref_primary_10_3390_cancers12123591
crossref_primary_10_3390_ijms22147518
crossref_primary_10_1111_jre_13055
crossref_primary_10_1016_j_canlet_2021_10_037
crossref_primary_10_1111_ddg_15340
crossref_primary_10_1186_s13256_021_02671_2
crossref_primary_10_1159_000530113
crossref_primary_10_1111_ddg_14694
crossref_primary_10_1136_jitc_2021_002990
crossref_primary_10_1186_s12967_023_04838_5
crossref_primary_10_33590_emjoncol_20_00251
crossref_primary_10_3390_ijms23084125
crossref_primary_10_3390_dermato1010003
crossref_primary_10_1016_j_labinv_2024_100323
crossref_primary_10_1016_j_bbrc_2023_04_018
crossref_primary_10_3390_ijms232416032
crossref_primary_10_1016_j_bbcan_2024_189159
crossref_primary_10_1002_cncr_34370
crossref_primary_10_1002_cncr_34372
crossref_primary_10_1111_ddg_15340_g
crossref_primary_10_3390_biomedicines11123290
crossref_primary_10_1038_s41467_024_55659_z
crossref_primary_10_1002_cam4_4425
crossref_primary_10_1136_jitc_2021_004149
crossref_primary_10_1159_000531490
crossref_primary_10_1002_gcc_23017
crossref_primary_10_1007_s11864_025_01307_7
crossref_primary_10_1097_CCO_0000000000001046
crossref_primary_10_2174_1568009623666221027101637
crossref_primary_10_1007_s11864_021_00858_9
crossref_primary_10_1002_path_6072
crossref_primary_10_1007_s44178_024_00080_1
crossref_primary_10_3390_ani14081224
crossref_primary_10_3390_biomedicines9081048
crossref_primary_10_1002_1878_0261_13744
crossref_primary_10_3390_cancers14235938
crossref_primary_10_3390_cancers13194816
crossref_primary_10_1016_j_jcms_2024_01_005
crossref_primary_10_1038_s42003_023_04856_5
crossref_primary_10_3390_ijms252212064
crossref_primary_10_1016_j_ejca_2024_114188
crossref_primary_10_1038_s41523_022_00413_1
crossref_primary_10_1007_s13577_022_00736_y
crossref_primary_10_3389_fonc_2023_1130215
crossref_primary_10_18632_oncotarget_27996
crossref_primary_10_1007_s12282_023_01535_5
crossref_primary_10_1038_s41417_024_00867_4
crossref_primary_10_1002_gcc_23268
crossref_primary_10_1038_s41698_021_00150_x
crossref_primary_10_1111_cas_14726
crossref_primary_10_1002_path_5873
crossref_primary_10_1158_1541_7786_MCR_23_1075
crossref_primary_10_1002_cncr_34403
crossref_primary_10_1016_j_bulcan_2023_03_002
crossref_primary_10_3389_fmed_2023_1090168
crossref_primary_10_3389_fonc_2022_1027696
crossref_primary_10_1016_j_anndiagpath_2022_152096
Cites_doi 10.3389/fimmu.2018.01209
10.1038/s41591-019-0749-z
10.1038/s41374-019-0295-9
10.1186/s13073-015-0126-6
10.1186/1471-2105-12-323
10.1186/s40425-019-0675-0
10.1016/S0140-6736(05)63203-5
10.1172/jci.insight.93652
10.1038/nm.3902
10.1007/s10549-017-4161-4
10.1093/bioinformatics/btp324
10.1126/scitranslmed.aad6352
10.1136/jmedgenet-2012-100918
10.1038/bjc.2014.359
10.1038/s41467-018-05032-8
10.1093/bioinformatics/bts635
10.1093/annonc/mdw281
10.1158/1078-0432.CCR-19-2180
10.2353/ajpath.2010.090637
10.1186/s40425-018-0404-0
10.1016/j.ymeth.2014.08.016
10.1158/0008-5472.CAN-09-2068
10.1002/cncr.27614
10.1016/j.cels.2015.12.004
10.4161/cbt.8.4.7547
10.1086/500561
10.1186/s40425-019-0499-y
10.1002/gcc.20827
10.1101/gr.230219.117
10.1186/gb-2011-12-4-r41
10.1016/S1470-2045(10)70023-1
10.1136/jclinpath-2012-200734
10.1038/s41598-017-13942-8
10.1186/s13058-016-0695-3
10.1128/JVI.65.11.6260-6265.1991
10.1001/jamaoncol.2019.1549
10.1038/ng.2921
10.1128/JVI.75.24.12347-12358.2001
10.1056/NEJMoa1603702
10.1158/1078-0432.CCR-18-0309
10.1038/ncomms9383
10.1093/bioinformatics/btv710
10.1172/JCI91190
10.1038/nature13954
10.1186/s13059-014-0550-8
10.1016/j.humpath.2014.01.008
10.1136/jclinpath-2019-206252
10.1093/nar/gkv1189
10.1038/s41586-020-1943-3
10.18632/oncotarget.5503
10.1126/science.aar3593
10.1093/bioinformatics/btv098
10.1093/annonc/mdm381
10.1186/s40425-018-0367-1
10.1016/j.pathol.2017.11.087
10.1097/PAS.0000000000000582
10.1158/1078-0432.CCR-17-2156
10.18632/oncotarget.5936
10.3389/fonc.2014.00080
10.1038/s41586-019-1330-0
10.1158/2159-8290.CD-17-0605
10.4049/jimmunol.1502635
10.1158/1078-0432.CCR-18-2652
10.1136/gutjnl-2015-310814
10.1159/000354215
10.1158/0008-5472.CAN-14-1162
10.1038/s41587-019-0114-2
10.1038/nbt.1883
10.1038/s41592-018-0051-x
10.1056/NEJMc1713444
10.3389/fimmu.2019.02093
ContentType Journal Article
Copyright COPYRIGHT 2020 American Society for Clinical Investigation
Copyright American Society for Clinical Investigation Nov 2020
2020 American Society for Clinical Investigation 2020 American Society for Clinical Investigation
Copyright_xml – notice: COPYRIGHT 2020 American Society for Clinical Investigation
– notice: Copyright American Society for Clinical Investigation Nov 2020
– notice: 2020 American Society for Clinical Investigation 2020 American Society for Clinical Investigation
DBID RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7RV
7X7
7XB
88A
88E
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
S0X
7X8
5PM
DOI 10.1172/jci139080
DatabaseName CiNii Complete
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
Biological Science Collection
eLibrary
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
SIRS Editorial
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
SIRS Editorial
elibrary
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
ProQuest Central Student
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1558-8238
EndPage 5846
ExternalDocumentID PMC7598061
A641057627
33016928
10_1172_JCI139080
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Singapore
GeographicLocations_xml – name: Singapore
GrantInformation_xml – fundername: SingHealth Duke-NUS Academic Medical Centre and Oncology ACP
  grantid: 08-FY2017/P1/14-A28
– fundername: Singapore Ministry of Health’s National Medical Research Council
  grantid: NMRC/Fellowship/0054/2017
– fundername: Singapore Ministry of Health’s National Medical Research Council
  grantid: NMRC/STAR/0006/2009
– fundername: SHF-Foundation Research Grant
  grantid: SHF/FG653P/2017
GroupedDBID ---
-~X
.55
.XZ
08G
08P
29K
354
36B
5GY
5RE
5RS
7RV
7X7
88E
8AO
8F7
8FE
8FH
8FI
8FJ
8R4
8R5
AAWTL
ABOCM
ABPMR
ABUWG
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFCHL
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ASPBG
AVWKF
AZFZN
BAWUL
BBNVY
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
CS3
D-I
DIK
DU5
E3Z
EBD
EBS
EJD
EMB
EMOBN
EX3
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
IOF
IOV
IPO
ISR
ITC
KQ8
L7B
LK8
M1P
M5~
M7P
NAPCQ
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OK1
OVD
OVIDX
OVT
P2P
P6G
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
RPM
RYH
S0X
SJFOW
SV3
TEORI
TR2
TVE
UKHRP
VVN
W2D
WH7
WOQ
WOW
X7M
XSB
YFH
YHG
YKV
YOC
ZY1
~H1
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
PMFND
3V.
7XB
88A
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c702t-7b43f8e6fd6f493b48cb514c80145ad6b9a69ba74c3529f2efb1f8ed25e42e303
IEDL.DBID 7X7
ISSN 0021-9738
1558-8238
IngestDate Thu Aug 21 18:22:27 EDT 2025
Fri Jul 11 05:09:23 EDT 2025
Fri Jul 25 09:11:17 EDT 2025
Tue Jun 17 21:16:25 EDT 2025
Thu Jun 12 23:43:29 EDT 2025
Tue Jun 10 20:42:29 EDT 2025
Fri Jun 27 03:35:52 EDT 2025
Fri Jun 27 05:04:51 EDT 2025
Thu May 22 21:20:29 EDT 2025
Mon Jul 21 06:03:56 EDT 2025
Tue Jul 01 00:21:50 EDT 2025
Thu Apr 24 23:09:38 EDT 2025
Thu Jun 26 22:27:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Genetics
Oncology
Cancer immunotherapy
Bioinformatics
Cancer
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c702t-7b43f8e6fd6f493b48cb514c80145ad6b9a69ba74c3529f2efb1f8ed25e42e303
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Authorship note: JYC, JQL, and JY are co–first authors and contributed equally to this work.
ORCID 0000-0003-3732-8707
0000-0002-4801-3703
0000-0002-7717-7416
0000-0002-7518-4081
0000-0001-8592-5018
0000-0001-9958-0137
0000-0001-6402-4288
0000-0003-1514-1124
0000-0002-0179-8048
OpenAccessLink https://cir.nii.ac.jp/crid/1872835443048720256
PMID 33016928
PQID 2458776629
PQPubID 42166
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7598061
proquest_miscellaneous_2448635665
proquest_journals_2458776629
gale_infotracmisc_A641057627
gale_infotracgeneralonefile_A641057627
gale_infotracacademiconefile_A641057627
gale_incontextgauss_ISR_A641057627
gale_incontextgauss_IOV_A641057627
gale_healthsolutions_A641057627
pubmed_primary_33016928
crossref_citationtrail_10_1172_JCI139080
crossref_primary_10_1172_JCI139080
nii_cinii_1872835443048720256
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20201101
PublicationDateYYYYMMDD 2020-11-01
PublicationDate_xml – month: 11
  year: 2020
  text: 20201101
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Ann Arbor
PublicationTitle Journal of Clinical Investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 2020
Publisher American Society for Clinical Investigation
Publisher_xml – name: American Society for Clinical Investigation
References B20
B64
B21
B65
B22
B66
B23
B67
B24
B26
B27
B28
B29
Li (B55) 2011; 12
B70
B72
B30
B31
B32
B33
Feng (B71) 2017; 2
B35
B36
B37
B38
B39
B1
B2
B3
B4
Yeong (B69) 2018; 9
B5
B6
B7
B8
Calvete (B16) 2015; 6
B9
B40
B41
B42
B43
B44
B45
B46
B47
B48
B49
Lam (B68) 2019; 10
B50
Subramaniam (B18) 2014; 4
B51
B52
Johnson (B25) 2018; 24
B53
B10
B54
B11
B12
B56
B13
B57
B14
B58
B15
B59
B17
B19
Hoyt (B34) 2019; 79
B60
B61
B62
B63
References_xml – volume: 9
  year: 2018
  ident: B69
  article-title: High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.01209
– ident: B10
  doi: 10.1038/s41591-019-0749-z
– ident: B36
  doi: 10.1038/s41374-019-0295-9
– ident: B45
  doi: 10.1186/s13073-015-0126-6
– volume: 12
  year: 2011
  ident: B55
  article-title: RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome
  publication-title: BMC Bioinformatics
  doi: 10.1186/1471-2105-12-323
– ident: B35
  doi: 10.1186/s40425-019-0675-0
– ident: B39
  doi: 10.1016/S0140-6736(05)63203-5
– volume: 2
  issue: 14
  year: 2017
  ident: B71
  article-title: Multiparametric immune profiling in HPV- oral squamous cell cancer
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.93652
– ident: B61
  doi: 10.1038/nm.3902
– volume: 79
  issue: 13 Suppl
  year: 2019
  ident: B34
  article-title: Abstract LB-318: Multi-institutional TSA-amplified multiplexed immunofluorescence reproducibility evaluation (MITRE study): reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow
  publication-title: Cancer Res
– ident: B63
  doi: 10.1007/s10549-017-4161-4
– ident: B43
  doi: 10.1093/bioinformatics/btp324
– ident: B65
  doi: 10.1126/scitranslmed.aad6352
– ident: B48
  doi: 10.1136/jmedgenet-2012-100918
– ident: B21
  doi: 10.1038/bjc.2014.359
– ident: B29
  doi: 10.1038/s41467-018-05032-8
– ident: B53
  doi: 10.1093/bioinformatics/bts635
– ident: B17
  doi: 10.1093/annonc/mdw281
– ident: B9
  doi: 10.1158/1078-0432.CCR-19-2180
– ident: B7
  doi: 10.2353/ajpath.2010.090637
– ident: B26
  doi: 10.1186/s40425-018-0404-0
– ident: B59
  doi: 10.1016/j.ymeth.2014.08.016
– ident: B8
  doi: 10.1158/0008-5472.CAN-09-2068
– ident: B14
  doi: 10.1002/cncr.27614
– ident: B57
  doi: 10.1016/j.cels.2015.12.004
– ident: B20
  doi: 10.4161/cbt.8.4.7547
– ident: B41
  doi: 10.1086/500561
– ident: B37
  doi: 10.1186/s40425-019-0499-y
– ident: B4
  doi: 10.1002/gcc.20827
– ident: B50
  doi: 10.1101/gr.230219.117
– ident: B52
  doi: 10.1186/gb-2011-12-4-r41
– ident: B2
  doi: 10.1016/S1470-2045(10)70023-1
– ident: B70
  doi: 10.1136/jclinpath-2012-200734
– ident: B33
  doi: 10.1038/s41598-017-13942-8
– ident: B64
  doi: 10.1186/s13058-016-0695-3
– ident: B40
  doi: 10.1128/JVI.65.11.6260-6265.1991
– ident: B31
  doi: 10.1001/jamaoncol.2019.1549
– ident: B5
  doi: 10.1038/ng.2921
– ident: B42
  doi: 10.1128/JVI.75.24.12347-12358.2001
– ident: B66
  doi: 10.1056/NEJMoa1603702
– volume: 24
  start-page: 5250
  issue: 21
  year: 2018
  ident: B25
  article-title: Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0309
– volume: 6
  year: 2015
  ident: B16
  article-title: A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families
  publication-title: Nat Commun
  doi: 10.1038/ncomms9383
– ident: B51
  doi: 10.1093/bioinformatics/btv710
– ident: B22
  doi: 10.1172/JCI91190
– ident: B28
  doi: 10.1038/nature13954
– ident: B56
  doi: 10.1186/s13059-014-0550-8
– ident: B60
  doi: 10.1016/j.humpath.2014.01.008
– ident: B32
  doi: 10.1136/jclinpath-2019-206252
– ident: B54
  doi: 10.1093/nar/gkv1189
– ident: B49
  doi: 10.1038/s41586-020-1943-3
– ident: B13
  doi: 10.18632/oncotarget.5503
– ident: B24
  doi: 10.1126/science.aar3593
– ident: B44
  doi: 10.1093/bioinformatics/btv098
– ident: B1
  doi: 10.1093/annonc/mdm381
– ident: B11
  doi: 10.1186/s40425-018-0367-1
– ident: B38
  doi: 10.1016/j.pathol.2017.11.087
– ident: B6
  doi: 10.1097/PAS.0000000000000582
– ident: B27
  doi: 10.1158/1078-0432.CCR-17-2156
– ident: B15
  doi: 10.18632/oncotarget.5936
– volume: 4
  year: 2014
  ident: B18
  article-title: DNA methyltransferases: a novel target for prevention and therapy
  publication-title: Front Oncol
  doi: 10.3389/fonc.2014.00080
– ident: B72
  doi: 10.1038/s41586-019-1330-0
– ident: B19
  doi: 10.1158/2159-8290.CD-17-0605
– ident: B67
  doi: 10.4049/jimmunol.1502635
– ident: B30
  doi: 10.1158/1078-0432.CCR-18-2652
– ident: B62
  doi: 10.1136/gutjnl-2015-310814
– ident: B3
  doi: 10.1159/000354215
– ident: B12
  doi: 10.1158/0008-5472.CAN-14-1162
– ident: B58
  doi: 10.1038/s41587-019-0114-2
– ident: B46
  doi: 10.1038/nbt.1883
– ident: B47
  doi: 10.1038/s41592-018-0051-x
– ident: B23
  doi: 10.1056/NEJMc1713444
– volume: 10
  year: 2019
  ident: B68
  article-title: Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.02093
SSID ssj0014454
ssib051604867
ssib058493170
ssib000343111
Score 2.574944
Snippet Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients,...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
nii
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5833
SubjectTerms Angiosarcoma
Biomedical research
Cancer immunotherapy
Care and treatment
CD8 antigen
Cell Line, Tumor
Cytotoxicity
Diagnosis
DNA methylation
DNMT1 protein
Epigenetics
Female
Foxp3 protein
Gene expression
Genetic aspects
Genomes
Head and neck
Hemangiosarcoma
Hemangiosarcoma - classification
Hemangiosarcoma - genetics
Hemangiosarcoma - immunology
Humans
Immunofluorescence
Immunohistochemistry
Immunotherapy
Inflammation
Inflammation - classification
Inflammation - genetics
Inflammation - immunology
Leukocytes (neutrophilic)
Lymphedema
Lymphocytes T
Macrophages
Male
Medical prognosis
Methods
Molecular diagnostic techniques
Mutation
Myc protein
Neck
Neoplasm Proteins
Neoplasm Proteins - genetics
Neoplasm Proteins - immunology
Oncology
Patients
PD-L1 protein
Precision medicine
Radiation therapy
Tumor-infiltrating lymphocytes
Tumors
Whole genome sequencing
Title Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
URI https://cir.nii.ac.jp/crid/1872835443048720256
https://www.ncbi.nlm.nih.gov/pubmed/33016928
https://www.proquest.com/docview/2458776629
https://www.proquest.com/docview/2448635665
https://pubmed.ncbi.nlm.nih.gov/PMC7598061
Volume 130
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFeEN9kbCMgBLxEW_2dJzTGpnVoAw2K-hbFjl0qsWSQ9v_nznHDgirES9XKv1jp5Xx3du5-R8irktlcCAWRm7E6Aw_tM3Ngbca0kVXuS6cCkfb5hTyd8LOpmMYDtzamVa5sYjDUVWPxjHyfcqGVkpLm765_Ztg1Ct-uxhYaG2QLqctQq9W033DBXkFEFuZRliumI7MQ-Oz9s6MxxD6BDfKGP4pWeaOez9dFnH8nTt7wRCf3yN0YQqaH3TO_T265-gG5fR5fkj8kk1BUi9XGaRkpR-BLlc6xFKTpmnSDw0qRvAnmqXCV13aRtkuDB7Jt2vg0tO6Dq2bzpoWl0FyVj8jk5Pjr0WkWuydkVh3QBQifM6-d9JX0PGeGa2sgOrJIFyPKSpq8lLkpFbcQg-WeOm9GgK-ocJw68GyPyWbd1O4pSVnOpFUUQpEKAo6qgk2hGxkqtVUGwhOfkLcrGRY2Uotjh4sfRdhiKFr04k7Iyx563fFprAM9xwdRdKWg_RosDiUmpYL5VjBNQCCDRY0pMrNy2bbF-NO3_wB9uRyA3kSQb-CebRnLEuCfIzPWAPl6gJx1vODrgDsDICxYOxjeBf0CQeHnSCtkvOOcgSlFEQsJl680r4gGpS3-qH9CXvTDODMmydWuWSKGa6QblCIhTzpF7WXMGNLuUJ0QNVDhHoA048ORev490I0rkWuI-rb_fVvPyB2KRxGhTHOHbC5-Ld0uxGsLsxcW5R7Zen988fkSfn0Yf_wNGHg-CA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbaIkEviDeBlgbE6xJ110ls54BQVah2226RoFvtLcSOvY0ESSG7QvwpfiMzjhMatEJcelmtlC-WMxnPw_F8Q8jzLFRJHHOI3KQSAXhoE8iBUkEoJMsTk2luibQnJ2w0jQ5n8WyN_GprYfBYZWsTraHOK4V75Ls0igXnjNHk7cW3ALtG4dfVtoVGoxZH-ucPSNnqN-N38H5fUHrw_nR_FLiuAoHiA7qASUWhEZqZnJkoCWUklISoQSGNSpzlTCYZS2TGIwWxSWKoNnII-JzGOqIaLD6Mu06ugeMdYLLHZ12CB7lJ7Fifh0HCQ-GYjCBG2D3cH0OsZdknL_k_5wXWy6JYFeH-fVDzkuc7uEVuupDV32t07DZZ0-Udcn3iPsrfJVNbxIvVzX7mKE7gT-4XWHpSNU3BwUH6SBYF4-RoVUq18OulxA3g2q-Mb1sFwl3zoqpBxtXX7B6ZXolc75ONsir1Q-KHScgUpxD65BDg5DkkoXooKROKSwiHjEdetzJMlaMyx44aX1Kb0nCaduL2yLMOetHwd6wC7eCLSJvS027Np3sMD8GCu-AwjEUgY0aJR3Lm2bKu0_GHs_8AffrYA71yIFPBnFXmyiDgyZGJq4d82UPOGx7yVcCtHhAMhOpd3gb9AkHh71BwZNiLohBMN4o4ZnB7q3mpM2B1-me5eeRpdxlHxkN5pa6WiIkE0huy2CMPGkXtZByGSPNDhUd4T4U7ANKa96-UxbmlN-dxIiDKfPTvae2QG6PTyXF6PD45ekw2KW6D2BLRLbKx-L7U2xArLuQTu0B98vmqLcJvdAF46A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa2Tpp4QdzJ2FhA3F6iro5jOw8IjW3VurEyDYr2FmLH7iJBMkgrxF_j13FO4oYFVYiXvVSV_MVKTk6OP1_Odwh5loY6jiIBzE1pGcAIbQO1o3UQSsWz2KZG1ELaJ2N-OGFH59H5Cvm1yIXBY5WLmFgH6qzUuEbepyySQnBO4751xyJO94dvLr8FWEEKd1oX5TQaFzk2P3_A9K16PdqHd_2c0uHBx73DwFUYCLTYoTO4QRZaabjNuGVxqJjUChiERkmVKM24ilMeq1QwDTwlttRYNQB8RiPDqIHoD_2ukjWBs6IeWXt7MD49a_cwGIucBvQgiEUona4RMIb-0d4ImFetRXllNHRjwmqR58v47t_HNq-Mg8Nb5KYjsP5u43G3yYop7pD1E7dFf5dM6pRezHX2Uyd4An8yP8dElLIpEQ7DpY_SUdBPhjGm0DO_mitcDq780vp14UC4apqXFVi5_JreI5Nrsex90ivKwjwkfhiHXAsKRCgDupNlMCU1A0W51EIBObIeebWwYaKdsDnW1_iS1BMcQZPW3B552kIvGzWPZaBtfBFJk4jaRoBkl-ORWBg8BHRTI1A_o0BPnKbzqkpG7z_9B-jDWQf00oFsCfesU5cUAU-Oulwd5IsOctqoki8DbnaAEC50p3kL_AsMhb8DKVBvj7EQAjmaOOJw-cLzEhfOquTPx-eRJ20z9oxH9ApTzhHDJIod8sgjDxpHbW0chij6Q6VHRMeFWwCKnHdbivyiFjsXUSyBc278-7a2yTpEg-TdaHz8iNyguCZS54tukt7s-9xsAXGcqcfuC_XJ5-sOCr8Btfx-gw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiomic+analysis+and+immunoprofiling+reveal+distinct+subtypes+of+human+angiosarcoma&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Chan%2C+Jason+Yongsheng&rft.au=Lim%2C+Jing+Quan&rft.au=Yeong%2C+Joe&rft.au=Ravi%2C+Vinod&rft.date=2020-11-01&rft.pub=American+Society+for+Clinical+Investigation&rft.issn=0021-9738&rft.volume=130&rft.issue=11&rft.spage=5833&rft_id=info:doi/10.1172%2FJCI139080&rft.externalDBID=IOV&rft.externalDocID=A641057627
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon